JO984B1
(en)
|
1977-10-11 |
1979-12-01 |
بيتشام غروب ليمتد |
A dry pharmaceutical compound with a suitable dosage unit for oral administration
|
US4513006A
(en)
|
1983-09-26 |
1985-04-23 |
Mcneil Lab., Inc. |
Anticonvulsant sulfamate derivatives
|
US5998380A
(en)
|
1995-10-13 |
1999-12-07 |
New England Medical Center Hospitals, Inc. |
Treatment of migraine
|
US5952187A
(en)
|
1995-12-01 |
1999-09-14 |
Oxis International, Inc. |
Topiramate immunoassay
|
US5753693A
(en)
|
1996-06-28 |
1998-05-19 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
|
WO1998000124A1
(en)
|
1996-06-28 |
1998-01-08 |
Ortho Pharmaceutical Corporation |
Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
|
RU2214241C2
(ru)
|
1996-06-28 |
2003-10-20 |
Орто-Макнейл Фармасьютикал, Инк. |
Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
|
SK284266B6
(sk)
|
1996-06-28 |
2004-12-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Antikonvulzívne deriváty vhodné na liečbu psoriázy
|
US5753694A
(en)
|
1996-06-28 |
1998-05-19 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
|
BR9712503A
(pt)
|
1996-10-08 |
1999-10-19 |
Ortho Mcneil Pharm Inc |
Derivados anticonvulsivos úteis no tratamento de dor neuropática
|
US6572880B2
(en)
|
1996-10-24 |
2003-06-03 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
CA2216215A1
(en)
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
US20080292700A1
(en)
|
1997-04-21 |
2008-11-27 |
Biovail Laboratories |
Controlled release formulations using intelligent polymers
|
ES2248908T7
(es)
|
1997-06-06 |
2014-11-24 |
Depomed, Inc. |
Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
US7744916B2
(en)
|
1997-06-11 |
2010-06-29 |
Umd, Inc. |
Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
|
US5760006A
(en)
|
1997-06-23 |
1998-06-02 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating psoriasis
|
US5935933A
(en)
|
1997-07-16 |
1999-08-10 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating neuropathic pain
|
US5760007A
(en)
|
1997-07-16 |
1998-06-02 |
Ortho Pharmaceutical Corporation |
Anticonvulsant derivatives useful in treating neuropathic pain
|
US6622036B1
(en)
|
2000-02-09 |
2003-09-16 |
Cns Response |
Method for classifying and treating physiologic brain imbalances using quantitative EEG
|
UA65607C2
(uk)
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
JP2002519373A
(ja)
|
1998-07-02 |
2002-07-02 |
エーザイ株式会社 |
製薬組成物及びそれらの使用
|
AU8761698A
(en)
|
1998-07-30 |
2000-02-21 |
Procter & Gamble Company, The |
Hair care compositions
|
US6890951B2
(en)
|
1998-08-05 |
2005-05-10 |
Brookhaven Science Associates Llc |
Treatment of addiction and addiction-related behavior
|
US6541520B1
(en)
|
1998-08-05 |
2003-04-01 |
Brookhaven Science Associates |
Treatment of addiction and addiction-related behavior
|
NZ511173A
(en)
|
1998-10-20 |
2003-09-26 |
Ortho Mcneil Pharm Inc |
Method for treating alcohol dependency, addiction and abuse using anticonvulsant derivatives (such as 2,3:4,5-bis- O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (topiramate))
|
US20010055613A1
(en)
|
1998-10-21 |
2001-12-27 |
Beth A. Burnside |
Oral pulsed dose drug delivery system
|
EP1002535A1
(en)
|
1998-10-28 |
2000-05-24 |
Hrissanthi Ikonomidou |
New use of glutamate antagonists for the treatment of cancer
|
PT1143917E
(pt)
|
1998-11-17 |
2004-06-30 |
Ortho Mcneil Pharm Inc |
Derivados anticonvulsionantes uteis no tratamento da perturbacao de stress pos-traumatico
|
AU1909700A
(en)
|
1998-12-03 |
2000-06-19 |
Ortho-Mcneil Pharmaceutical, Inc. |
Topiramate and related derivatives for treating Schizophrenia
|
US7214711B2
(en)
|
1998-12-23 |
2007-05-08 |
Neurotherapeutics Pharma Llc |
Method of treating migraine headache without aura
|
IL144406A0
(en)
|
1999-01-19 |
2002-05-23 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in treating cluster headaches
|
AR022321A1
(es)
|
1999-01-21 |
2002-09-04 |
Ortho Mcneil Pharm Inc |
Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
|
WO2000044353A1
(de)
*
|
1999-01-29 |
2000-08-03 |
Losan Pharma Gmbh |
Pharmazeutische zusammensetzungen
|
HUP0105420A3
(en)
|
1999-02-01 |
2003-03-28 |
Ortho Mcneil Pharm Inc |
Use of anticonvulsant derivatives for treating bulimia nervosa
|
DK1152756T3
(da)
|
1999-02-08 |
2005-10-10 |
Ortho Mcneil Pharm Inc |
Anticonvulsiva til behandling af autisme
|
DK1158950T3
(da)
|
1999-02-17 |
2006-04-24 |
Ortho Mcneil Pharm Inc |
antikonvulsive derivater til behandling af essentiel tremor
|
DK1158973T3
(da)
|
1999-02-24 |
2005-05-30 |
Univ Cincinnati |
Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
CA2369093C
(en)
|
1999-04-08 |
2005-10-18 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in lowering lipids
|
MXPA01010221A
(es)
|
1999-04-08 |
2002-03-27 |
Johnson & Johnson |
Derivados anticonvulsivos utiles para disminuir la presion sanguinea.
|
JP2003530300A
(ja)
|
1999-04-08 |
2003-10-14 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
体重低下を維持することに有用な抗痙攣薬誘導体
|
NZ514811A
(en)
|
1999-04-08 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in reducing blood glucose levels
|
WO2000066108A2
(en)
|
1999-04-30 |
2000-11-09 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating cocaine dependency
|
AU4307800A
(en)
|
1999-04-30 |
2000-11-17 |
Merab Lomia |
New indication for use of antiepileptic agents and medicines
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
EP1187604A4
(en)
|
1999-05-28 |
2004-02-11 |
Jeffrey Berlant |
CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US20080255093A1
(en)
|
1999-06-14 |
2008-10-16 |
Tam Peter Y |
Compositions and methods for treating obesity and related disorders
|
US7659256B2
(en)
|
1999-06-14 |
2010-02-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
US7674776B2
(en)
|
1999-06-14 |
2010-03-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
US7553818B2
(en)
|
1999-06-14 |
2009-06-30 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
EP1210118B1
(en)
|
1999-08-20 |
2004-12-08 |
Ortho-McNeil Pharmaceutical, Inc. |
Composition comprising a tramadol material and an anticonvulsant drug
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
US6887870B1
(en)
|
1999-10-12 |
2005-05-03 |
Bristol-Myers Squibb Company |
Heterocyclic sodium/proton exchange inhibitors and method
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US10179159B2
(en)
|
1999-10-22 |
2019-01-15 |
Scott Wepfer |
Topical anesthetic formulation
|
US6479467B1
(en)
|
1999-12-16 |
2002-11-12 |
Eastman Chemical Company |
Cyclodextrin ethers
|
MXPA02007254A
(es)
|
2000-02-04 |
2002-12-09 |
Depomed Inc |
Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
|
SE0000601D0
(sv)
|
2000-02-24 |
2000-02-24 |
Jan Hedner |
Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6555519B2
(en)
|
2000-03-30 |
2003-04-29 |
Bristol-Myers Squibb Company |
O-glucosylated benzamide SGLT2 inhibitors and method
|
US6683056B2
(en)
|
2000-03-30 |
2004-01-27 |
Bristol-Myers Squibb Company |
O-aryl glucoside SGLT2 inhibitors and method
|
US20010036943A1
(en)
|
2000-04-07 |
2001-11-01 |
Coe Jotham W. |
Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
|
EP1157682A1
(en)
|
2000-05-25 |
2001-11-28 |
Cilag AG |
Blister package for topiramate tablets
|
US20020013334A1
(en)
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
US20020028826A1
(en)
|
2000-06-15 |
2002-03-07 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
WO2002000221A1
(en)
|
2000-06-23 |
2002-01-03 |
University Of Utah Research Foundation |
Enhanced brain function by gaba-ergic stimulation
|
AU2001280486A1
(en)
|
2000-07-07 |
2002-01-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
US6946243B2
(en)
|
2000-07-20 |
2005-09-20 |
Solvay Pharmaceuticals Gmbh |
Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
|
CA2417304A1
(en)
|
2000-08-02 |
2002-02-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of depression
|
US6395783B1
(en)
|
2000-10-23 |
2002-05-28 |
Brookhaven Science Associates, Llc |
Treatment of PCP addiction and PCP addiction-related behavior
|
ATE334718T1
(de)
|
2000-10-30 |
2006-08-15 |
Ortho Mcneil Pharm Inc |
Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
|
US20050136106A1
(en)
|
2000-11-20 |
2005-06-23 |
Adrian Sandler |
Therapeutic placebo enhancement of commonly used medications
|
WO2002043762A2
(en)
|
2000-11-30 |
2002-06-06 |
Pfizer Products Inc. |
Combination of gaba agonists and sorbitol dehydrogenase inhibitors
|
EP1337272A2
(en)
|
2000-11-30 |
2003-08-27 |
Pfizer Products Inc. |
Combination of gaba agonists and aldose reductase inhibitors
|
RU2317086C2
(ru)
|
2001-02-02 |
2008-02-20 |
Орто-Макнейл Фармасьютикал, Инк. |
Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US20060198815A1
(en)
|
2001-03-19 |
2006-09-07 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained release
|
JP4499362B2
(ja)
|
2001-03-28 |
2010-07-07 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ニューロパシーの疼痛を処置するためのニューブラスチンポリペプチドの使用
|
US20070026440A1
(en)
|
2001-04-06 |
2007-02-01 |
Broderick Patricia A |
Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors, and brain and spinal cord injuries using electrodes with microvoltammetry
|
US8257746B2
(en)
|
2001-04-10 |
2012-09-04 |
Pernix Therapeutics, Llc |
Tannate compositions, methods of making and methods of use
|
US8012506B2
(en)
|
2001-04-10 |
2011-09-06 |
Pernix Therapeutics, Llc |
Tannate compositions, methods of making and methods of use
|
AU2002254567B2
(en)
|
2001-04-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
US6573287B2
(en)
|
2001-04-12 |
2003-06-03 |
Bristo-Myers Squibb Company |
2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
|
US20030109546A1
(en)
|
2001-04-26 |
2003-06-12 |
Fenton Wayne S. |
Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
|
US20020187996A1
(en)
|
2001-05-14 |
2002-12-12 |
Dewey Stephen L. |
Prevention of addiction in pain management
|
US6462084B1
(en)
|
2001-05-14 |
2002-10-08 |
Brookhaven Science Associates, Llc |
Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US6967212B2
(en)
|
2001-05-30 |
2005-11-22 |
Bristol-Myers Squibb Company |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
DE10127134A1
(de)
|
2001-06-05 |
2002-12-12 |
Roehm Gmbh |
verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß
|
GB0113663D0
(en)
|
2001-06-05 |
2001-07-25 |
Novartis Ag |
Use of organic compounds
|
UA78211C2
(en)
|
2001-07-09 |
2007-03-15 |
Ortho Mcneil Pharm Inc |
Salts of fructopyranose derivatives as anticonvulsant
|
WO2003006006A1
(en)
|
2001-07-09 |
2003-01-23 |
The Regents Of The University Of California |
Use of matrix metalloproteinase inhibitors to mitigate nerve damage
|
US7041650B2
(en)
|
2001-07-09 |
2006-05-09 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivative salts
|
EP2275959A3
(en)
|
2001-07-11 |
2011-04-06 |
CNS Response, Inc. |
Method of screening a therapeutic agent for therapeutic effectiveness
|
US20030032661A1
(en)
|
2001-08-02 |
2003-02-13 |
Boehringer Ingelheim Pharma Kg |
Pramipexole as an anticonvulsant
|
WO2003011271A2
(en)
|
2001-08-03 |
2003-02-13 |
Children's Medical Center Corporation |
Methods and compositions for modulating brain damage
|
US20060173064A1
(en)
|
2001-08-24 |
2006-08-03 |
Lippa Arnold S |
(-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
|
JP2005502680A
(ja)
|
2001-08-30 |
2005-01-27 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
抗痙攣剤およびアセチルコリンエステラーゼ阻害剤による痴呆および記憶障害の処置
|
WO2003020737A1
(en)
|
2001-09-05 |
2003-03-13 |
Bristol-Myers Squibb Company |
O-pyrazole glucoside sglt2 inhibitors and method of use
|
EP1429787A1
(en)
|
2001-09-24 |
2004-06-23 |
Ortho-McNeil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
|
US20030072802A1
(en)
|
2001-10-11 |
2003-04-17 |
R.T. Alamo Ventures, Inc. |
Sustained release topiramate
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
DE10153078A1
(de)
|
2001-10-30 |
2003-05-22 |
Degussa |
Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
|
EP1442028A4
(en)
|
2001-11-06 |
2009-11-04 |
Bristol Myers Squibb Co |
SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
|
US8329217B2
(en)
*
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20030092636A1
(en)
|
2001-11-06 |
2003-05-15 |
Silberstein Stephen D. |
Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
|
MXPA04004572A
(es)
|
2001-11-14 |
2005-07-05 |
Ralph Ryback |
Metodo para el tratamiento de enfermedades autoinmunes.
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
US20070167853A1
(en)
|
2002-01-22 |
2007-07-19 |
Melker Richard J |
System and method for monitoring health using exhaled breath
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
US6559293B1
(en)
|
2002-02-15 |
2003-05-06 |
Transform Pharmaceuticals, Inc. |
Topiramate sodium trihydrate
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7446107B2
(en)
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
MXPA04008259A
(es)
|
2002-02-26 |
2005-05-27 |
Johnson & Johnson |
Co-terapia para el tratamiento de migrana que comprende derivados de un anticonvulsivo y agentes anti-migrana.
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
ES2399880T3
(es)
|
2002-03-15 |
2013-04-04 |
Cypress Bioscience, Inc. |
Milnaciprán para el tratamiento del síndrome del intestino irritable
|
US20070021356A1
(en)
|
2002-03-18 |
2007-01-25 |
Cady Roger K |
Preemptive prophlyaxis of migraine
|
DE60322371D1
(de)
|
2002-03-29 |
2008-09-04 |
Alza Corp |
Volumensparende arzneiform zur kontrollierten freisetzung
|
US20040005358A1
(en)
|
2002-04-23 |
2004-01-08 |
Slugg Peter H. |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
ATE425744T1
(de)
|
2002-04-29 |
2009-04-15 |
Supernus Pharmaceuticals Inc |
Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
|
US7060725B2
(en)
|
2002-05-13 |
2006-06-13 |
Janssen Pharmaceutica N.V. |
Substituted sulfamate anticonvulsant derivatives
|
AU2003239455A1
(en)
|
2002-05-14 |
2003-12-02 |
Ralph Ryback |
Method for treating dermatoses and tissue damage
|
US7109198B2
(en)
|
2002-05-17 |
2006-09-19 |
Duke University |
Method for treating obesity
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
EP1364649A1
(en)
|
2002-05-23 |
2003-11-26 |
Cilag AG |
Adduct of topiramate and tramadol hydrochioride and uses thereof
|
EP1511490A4
(en)
|
2002-05-31 |
2009-03-11 |
Transform Pharmaceuticals Inc |
NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
US20040063751A1
(en)
|
2002-05-31 |
2004-04-01 |
Pharmacia Corporation |
Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug
|
US20030235576A1
(en)
|
2002-06-15 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drug combinations for the treatment of ischaemic conditions
|
US20070243254A1
(en)
|
2002-06-26 |
2007-10-18 |
David Edgren |
Novel drug compositions and dosage forms of topiramate
|
AR039744A1
(es)
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
US20040087513A1
(en)
|
2002-07-04 |
2004-05-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New drug combinations based on sodium channel blockers and magnesium salts
|
EP1531810B1
(en)
|
2002-07-09 |
2012-02-01 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
WO2004004665A2
(en)
|
2002-07-09 |
2004-01-15 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
AU2003253925A1
(en)
|
2002-07-18 |
2004-02-09 |
Banyu Pharmaceutical Co., Ltd. |
Combination therapy for the treatment of obesity
|
JP2006508042A
(ja)
|
2002-07-18 |
2006-03-09 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体の修飾物質および方法
|
NZ537543A
(en)
|
2002-07-29 |
2007-08-31 |
Alza Corp |
Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
|
MXPA05001549A
(es)
|
2002-08-08 |
2005-05-05 |
Kissei Pharmaceutical |
Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
|
JP2004137245A
(ja)
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
EP1402924B1
(de)
|
2002-09-04 |
2008-12-31 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verwendung eines Mittel zur Therapie der Herzhypertrophie
|
WO2004026299A1
(en)
|
2002-09-17 |
2004-04-01 |
Motac Neuroscience Limited |
Treatment of dyskinesia
|
AU2003218462A1
(en)
|
2002-10-01 |
2004-04-23 |
Merck And Co., Inc. |
Treatment of obesity and other disorders associated with excessive food intake
|
ATE469645T1
(de)
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US20040082543A1
(en)
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
US7196209B2
(en)
|
2002-10-31 |
2007-03-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Continuous process for the preparation of fructopyranose sulfamate derivatives
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
AU2003297639A1
(en)
|
2002-12-02 |
2004-06-23 |
University Of Florida |
Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
AU2003296672A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Cilag Ag |
Controlled release preparations comprising tramadol and topiramate
|
RU2005122035A
(ru)
*
|
2002-12-13 |
2006-01-20 |
Цилаг Аг (Ch) |
Стабильные препараты топирамата
|
ITMI20022658A1
(it)
|
2002-12-17 |
2004-06-18 |
Nicox Sa |
Farmaci per il dolore cronico.
|
EP1585500B8
(en)
|
2002-12-20 |
2017-07-26 |
Auritec Pharmaceuticals |
Coated particles for sustained-release pharmaceutical administration
|
WO2004058222A1
(en)
|
2002-12-20 |
2004-07-15 |
St. James Associates Llc/Faber Research Series |
High pressure compaction for pharmaceutical formulations
|
EP1587499A1
(en)
|
2003-01-31 |
2005-10-26 |
Elan Pharma International Limited |
Nanoparticulate topiramate formulations
|
ATE550022T1
(de)
|
2003-02-28 |
2012-04-15 |
Mcneil Ppc Inc |
Pharmazeutische mischkristalle von celecoxib- nicotinamid
|
EP1631260A2
(en)
|
2003-02-28 |
2006-03-08 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
UA81657C2
(ru)
|
2003-03-04 |
2008-01-25 |
Орто-Макнейл Фармасьютикел, Инк. |
Способ получения противосудорожных производных топирамата
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
WO2004089965A2
(en)
|
2003-04-07 |
2004-10-21 |
Cipla Ltd |
Topiramate and processes for the preparation thereof
|
PT1477166E
(pt)
|
2003-04-28 |
2006-12-29 |
Biofrontera Bioscience Gmbh |
Utilização de riluzole combinado com substâncias auxiliares e aditivos adequados, para o tratamento de doenças caracterizadas por uma hiperproliferação de queratinócitos, especialmente de neurodermite e psoríase
|
US20040229943A1
(en)
|
2003-05-16 |
2004-11-18 |
Cephalon Inc |
Analeptic and drug combinations
|
PL1626721T3
(pl)
|
2003-05-23 |
2017-05-31 |
Otsuka Pharmaceutical Co., Ltd. |
Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju
|
US20060160776A1
(en)
|
2003-05-28 |
2006-07-20 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
US20060160834A1
(en)
|
2003-06-06 |
2006-07-20 |
Fong Tung M |
Combination therapy for the treatment of hypertension
|
US20070099884A1
(en)
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
EP1635813A4
(en)
|
2003-06-06 |
2009-07-01 |
Merck & Co Inc |
COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
|
WO2005000294A1
(en)
|
2003-06-06 |
2005-01-06 |
Pharmacia Corporation |
Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7235662B2
(en)
|
2003-06-11 |
2007-06-26 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6949518B1
(en)
|
2003-06-25 |
2005-09-27 |
Pao-Hsien Chu |
Methods for treating macular degeneration with topiramate
|
US20090117181A1
(en)
*
|
2003-06-25 |
2009-05-07 |
Tomoyuki Uehara |
Tablet comprising fluvastatin and carmellose calcium
|
CN1812982B
(zh)
|
2003-06-26 |
2010-10-27 |
默沙东公司 |
苯并二氮杂*cgrp受体拮抗剂
|
CA2529196A1
(en)
|
2003-06-26 |
2005-02-17 |
Merck & Co., Inc. |
Benzodiazepine cgrp receptor antagonists
|
US20070111204A1
(en)
|
2003-06-27 |
2007-05-17 |
Kathleen Delgrosso |
Methods for detecting nucleic acid variations
|
WO2005007628A1
(en)
|
2003-07-11 |
2005-01-27 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2005016306A2
(en)
|
2003-08-06 |
2005-02-24 |
Alza Corporation |
Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
|
US20050031544A1
(en)
|
2003-08-07 |
2005-02-10 |
Njemanze Philip Chidi |
Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
|
WO2005020957A2
(en)
|
2003-08-22 |
2005-03-10 |
Alza Corporation |
Stepwise delivery of topiramate over prolonged period of time
|
EP1673064A1
(en)
|
2003-08-28 |
2006-06-28 |
Sandoz AG |
Pharmaceutical composition comprising anticonvulsant with taste mask coating
|
AU2004268661A1
(en)
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
US7611728B2
(en)
|
2003-09-05 |
2009-11-03 |
Supernus Pharmaceuticals, Inc. |
Osmotic delivery of therapeutic compounds by solubility enhancement
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005048979A2
(en)
|
2003-10-06 |
2005-06-02 |
Torrent Pharmaceuticals Limited |
Pharmaceutical composition having casing with multiple micro tablets
|
US7425410B2
(en)
|
2003-10-30 |
2008-09-16 |
Free State Diagnostics, Llc |
Methods for diagnosing a bipolar disorder and unipolar disorder
|
MXPA06005461A
(es)
|
2003-11-13 |
2006-12-15 |
Johnson & Johnson |
Dispersiones de mezclas en estado fundido que comprenden un farmaco de baja solubilidad en agua y un copolimero de bloque de oxido de etileno-oxido de propileno.
|
EP1684713A1
(en)
|
2003-11-14 |
2006-08-02 |
ALZA Corporation |
Controlled release of topirimate in liquid dosage forms
|
WO2005049043A1
(en)
|
2003-11-18 |
2005-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Combination therapy comprising metformin and anticonvulsant agents
|
US20050181049A1
(en)
|
2003-11-19 |
2005-08-18 |
Dong Liang C. |
Composition and method for enhancing bioavailability
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005063248A1
(en)
|
2003-12-22 |
2005-07-14 |
Sepracor Inc. |
Modafinil combination therapy for improving sleep quality
|
WO2005063206A1
(en)
|
2003-12-23 |
2005-07-14 |
Alza Corporation |
Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
|
AU2004308962A1
(en)
|
2003-12-24 |
2005-07-14 |
Sepracor Inc. |
Melatonin combination therapy for improving sleep quality
|
EP1701708A2
(en)
|
2003-12-29 |
2006-09-20 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
KR20060128995A
(ko)
|
2004-01-13 |
2006-12-14 |
듀크 유니버시티 |
체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US7326728B2
(en)
|
2004-01-16 |
2008-02-05 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
|
US7273881B2
(en)
|
2004-01-16 |
2007-09-25 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7253283B2
(en)
|
2004-01-16 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7625921B2
(en)
|
2004-01-16 |
2009-12-01 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7569689B2
(en)
|
2004-01-16 |
2009-08-04 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7605264B2
(en)
|
2004-01-16 |
2009-10-20 |
Bristol-Myers Squibb Company |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2005082372A1
(en)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US20050182105A1
(en)
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
ES2241478B1
(es)
|
2004-02-13 |
2006-11-16 |
Lacer S.A. |
Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
|
CA2556214A1
(en)
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
US20050181071A1
(en)
|
2004-02-18 |
2005-08-18 |
Binder Michael R. |
Method for the treatment of clinical depression
|
CN1934103B
(zh)
|
2004-03-04 |
2011-06-01 |
橘生药品工业株式会社 |
稠杂环衍生物,包含稠杂环衍生物的药物组合物及其医药用途
|
US7732596B2
(en)
|
2004-03-04 |
2010-06-08 |
Kissei Pharmaceutical Co., Ltd. |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
ZA200608029B
(en)
|
2004-03-04 |
2008-12-31 |
Kissei Pharmaceutical |
Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
|
US20050203287A1
(en)
|
2004-03-11 |
2005-09-15 |
Chandrasekhar Batchu |
Process for the preparation of sulfamate derivatives
|
TWI357901B
(en)
|
2004-03-12 |
2012-02-11 |
Lundbeck & Co As H |
Substituted morpholine and thiomorpholine derivati
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
ES2378071T3
(es)
|
2004-03-24 |
2012-04-04 |
Janssen Pharmaceutica Nv |
Moduladores de cannabinoides de tetrahidro-indazol
|
EP1732893A2
(en)
|
2004-03-29 |
2006-12-20 |
Pfizer Japan, Inc. |
Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
|
CA2560005A1
(en)
|
2004-03-31 |
2005-10-13 |
Kissei Pharmaceutical Co., Ltd. |
Phenol derivative, medicinal composition containing the same, and medicinal use thereof
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
GB0408308D0
(en)
|
2004-04-14 |
2004-05-19 |
Vectura Ltd |
Pharmaceutical compositions
|
WO2005110405A1
(en)
|
2004-05-03 |
2005-11-24 |
Duke University |
Compositions for affecting weight loss
|
US20050250838A1
(en)
*
|
2004-05-04 |
2005-11-10 |
Challapalli Prasad V |
Formulation for sustained delivery
|
WO2005113519A1
(en)
|
2004-05-14 |
2005-12-01 |
Irm Llc |
Compounds and compositions as ppar modulators
|
WO2005113506A1
(en)
|
2004-05-14 |
2005-12-01 |
Irm Llc |
Compounds and compositions as ppar modulators
|
PE20060362A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de oxazol como moduladores de ppar
|
US20070212428A1
(en)
|
2004-06-04 |
2007-09-13 |
Mood Management Sciences, Inc. |
Methods and compositions for treating mood disorder
|
CA2569411A1
(en)
|
2004-06-04 |
2005-12-22 |
Mood Management Sciences, Llc |
Methods and compositions for treating mood disorder
|
WO2006007323A2
(en)
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US20060110428A1
(en)
|
2004-07-02 |
2006-05-25 |
Eugene Dejuan |
Methods and devices for the treatment of ocular conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7829279B1
(en)
|
2004-07-16 |
2010-11-09 |
The Regents Of The University Of California |
Compositions and methods for diagnosis and treatment of epilepsy
|
CA2572928A1
(en)
|
2004-07-22 |
2006-02-26 |
Amorepacific Corporation |
Sustained-release preparations containing topiramate and the producing method thereof
|
WO2006017524A2
(en)
|
2004-08-02 |
2006-02-16 |
Olney John W |
Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
|
MX2007001563A
(es)
|
2004-08-04 |
2008-03-05 |
Johnson & Johnson |
Composicion para liberacion sostenida de farmaco que demuestra un patron de liberacion ascendente del orden cero, metodos para la elaboracion de dicha composicion.
|
WO2006015930A1
(en)
|
2004-08-10 |
2006-02-16 |
Nicox S.A. |
Phenol derivatives
|
EP1784390A2
(en)
|
2004-08-13 |
2007-05-16 |
Amgen Inc. |
Substituted benzofused heterocycles
|
DE602004002692T2
(de)
|
2004-08-19 |
2007-09-06 |
Helm Ag |
Verfahren zur Herstellung von Topiramate
|
US20060039866A1
(en)
|
2004-08-20 |
2006-02-23 |
Cypress Bioscience, Inc. |
Method for treating sleep-related breathing disorders
|
US7696192B2
(en)
|
2004-09-09 |
2010-04-13 |
Merck Sharp & Dohme Corp. |
Tricyclic anilide spirolactam CGRP receptor antagonists
|
AU2005285083B2
(en)
|
2004-09-13 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Tricyclic anilide spirohydantoin CGRP receptor antagonists
|
EP1797073B1
(en)
|
2004-09-13 |
2010-04-14 |
Merck Sharp & Dohme Corp. |
Bicyclic anilide spirolactam cgrp receptor antagonists
|
US20060058224A1
(en)
|
2004-09-15 |
2006-03-16 |
Yancopoulos George D |
Methods of treating obesity with combination therapeutics
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
CN101027075A
(zh)
|
2004-09-24 |
2007-08-29 |
默克公司 |
用于治疗肥胖的组合疗法
|
AU2005295787A1
(en)
|
2004-10-15 |
2006-04-27 |
Janssen Pharmaceutica, N.V. |
Carbamate compounds for use in treating neurodegenerative disorders
|
US20060088886A1
(en)
|
2004-10-25 |
2006-04-27 |
Anlong Ouyang |
Topiramate analogs
|
US7638291B2
(en)
|
2004-10-25 |
2009-12-29 |
Seradyn, Inc. |
Immunoassays for topiramate
|
US8779175B2
(en)
|
2004-10-25 |
2014-07-15 |
Synthonics, Inc. |
Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
|
US20080200376A1
(en)
|
2004-10-29 |
2008-08-21 |
Maccoss Malcolm |
Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
|
AU2005307772B2
(en)
|
2004-11-16 |
2010-06-10 |
Limerick Biopharma, Inc. |
Methods and compositions for treating pain
|
US20060121112A1
(en)
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
EA200701246A1
(ru)
*
|
2004-12-09 |
2008-06-30 |
Инсис Терапьютикс, Инк. |
Стабильные при комнатной температуре составы дронабинола
|
US20060129324A1
(en)
|
2004-12-15 |
2006-06-15 |
Biogenesys, Inc. |
Use of quantitative EEG (QEEG) alone and/or other imaging technology and/or
in combination with genomics and/or proteomics and/or biochemical analysis and/or other diagnostic modalities, and CART and/or AI and/or statistical and/or other mathematical analysis methods for improved medical and other diagnosis, psychiatric and other disease treatment, and also for veracity verification and/or lie detection applications.
|
GB0428170D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Mono and Combination Therapy
|
US8067217B2
(en)
*
|
2004-12-28 |
2011-11-29 |
Kaneka Corporation |
Method for preserving reduced coenzyme Q10
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7361654B2
(en)
|
2005-01-13 |
2008-04-22 |
Bristol-Myers Squibb Co. |
Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7411071B2
(en)
|
2005-01-13 |
2008-08-12 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
EP1841419A4
(en)
|
2005-01-19 |
2009-02-25 |
Merck Frosst Canada Ltd |
INHIBITORS OF CATHEPSIN K AND OBESITY
|
WO2006077492A1
(en)
*
|
2005-01-24 |
2006-07-27 |
Ranbaxy Laboratories Limited |
Sustained release oral dosage forms of gabapentin
|
WO2006080029A1
(en)
|
2005-01-27 |
2006-08-03 |
Alembic Limited |
Extended release formulation of levetiracetam
|
MX2007009356A
(es)
|
2005-02-03 |
2007-12-07 |
Irm Llc |
Compuestos y composiciones como moduladores de ppar.
|
US20090123563A1
(en)
|
2005-02-07 |
2009-05-14 |
Novo Nordisk A/S |
Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
|
WO2006088305A1
(en)
|
2005-02-15 |
2006-08-24 |
Chong Kun Dang Pharmaceutical Corp. |
Gastric-retentive controlled release mono-matrix tablet
|
MX2007010721A
(es)
|
2005-03-01 |
2007-11-13 |
Pfizer Ltd |
Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
IS7748A
(is)
|
2005-03-17 |
2006-09-18 |
Actavis Group |
Samsetning fyrir töflur sem innihalda topiramate
|
US20060211632A1
(en)
|
2005-03-17 |
2006-09-21 |
Bachmann Kenneth A |
PXR agonists for cardiovascular disease
|
AU2005215928A1
(en)
|
2005-03-18 |
2006-10-05 |
Ucl Biomedica Plc |
Genetic predictor for clinical use of drugs used in the treatment of neurological conditions
|
WO2006102029A2
(en)
|
2005-03-21 |
2006-09-28 |
Dov Pharmaceutical, Inc. |
Methods and compositions for the treatment of urinary incontinence
|
KR101288729B1
(ko)
|
2005-04-01 |
2013-07-23 |
인터자인 테크놀로지스, 인코포레이티드 |
약물 전달용 중합체성 마이셀
|
WO2006113095A2
(en)
|
2005-04-12 |
2006-10-26 |
Free State Diagnostics, Llc |
Methods for diagnosing a bipolar disorder and attention-deficit/hyperactivity disorder
|
JP5833804B2
(ja)
|
2005-04-13 |
2015-12-16 |
ニューラクソン,インコーポレーテッド |
Nos阻害活性を有する置換インドール化合物
|
US20110117070A1
(en)
|
2005-04-19 |
2011-05-19 |
Aurora Sheena K |
Compositions and methods for treating headache
|
US20060252745A1
(en)
|
2005-05-06 |
2006-11-09 |
Almeida Jose L D |
Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
|
PT2380573E
(pt)
|
2005-05-06 |
2015-06-11 |
Bial Portela & Ca Sa |
Acetato de eslicarbazepina e métodos de utilização
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
AR054045A1
(es)
|
2005-05-18 |
2007-05-30 |
Neuraxon Inc |
Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista
|
EP1901733B1
(en)
|
2005-05-23 |
2016-04-06 |
President and Fellows of Harvard College |
Huperzine for use in the treatment of neuropathic pain
|
RU2007142346A
(ru)
|
2005-05-31 |
2009-07-20 |
Ориксиджен Серапьютикс, Инкорпорэйтд (Сша/Сша) (Us) |
Способы и составы для контроля психотических нарушений
|
AU2006262441A1
(en)
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine H3 antagonists
|
EP1896453B1
(en)
|
2005-06-20 |
2009-12-02 |
Schering Corporation |
Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
|
WO2007001939A1
(en)
|
2005-06-27 |
2007-01-04 |
Janssen Pharmaceutica N.V. |
Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
|
WO2007002872A2
(en)
|
2005-06-29 |
2007-01-04 |
Alza Corporation |
Semi-permeable compositions providing reduced drying time for osmotic dosage forms
|
US20070021500A1
(en)
|
2005-07-12 |
2007-01-25 |
Twyman Roy E |
Methods for neuroprotection
|
US20070021501A1
(en)
|
2005-07-12 |
2007-01-25 |
Twyman Roy E |
Methods of treating epileptogenesis
|
KR20080042092A
(ko)
|
2005-07-27 |
2008-05-14 |
오렉시젠 세러퓨틱스 인크. |
체중감량 조성물
|
US8227476B2
(en)
|
2005-08-03 |
2012-07-24 |
Sprout Pharmaceuticals, Inc. |
Use of flibanserin in the treatment of obesity
|
WO2007026224A2
(en)
|
2005-08-31 |
2007-03-08 |
Pfizer Products Inc. |
5-ht1b antagonist composition for depression, anxiety and cognition
|
US20070276001A1
(en)
|
2005-09-14 |
2007-11-29 |
Concert Pharmaceuticals Inc. |
Biphenyl-pyrazolecarboxamide compounds
|
US7514068B2
(en)
|
2005-09-14 |
2009-04-07 |
Concert Pharmaceuticals Inc. |
Biphenyl-pyrazolecarboxamide compounds
|
JP2009508854A
(ja)
|
2005-09-16 |
2009-03-05 |
セリューサイエンス アーベー |
睡眠時呼吸障害の予防及び治療方法及び手段
|
DE602006013501D1
(de)
|
2005-09-16 |
2010-05-20 |
Janssen Pharmaceutica Nv |
Cyclopropylamine als modulatoren des histamin-h3-rezeptors
|
US7332604B2
(en)
|
2005-09-20 |
2008-02-19 |
Schering Corporation |
1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
|
CN101312952B
(zh)
|
2005-09-23 |
2012-12-26 |
詹森药业有限公司 |
四氢-环戊二烯并吡唑大麻素调节剂
|
US8378117B2
(en)
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US7825151B2
(en)
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
PL1931335T3
(pl)
|
2005-09-23 |
2010-07-30 |
Janssen Pharmaceutica Nv |
Modulatory heksahydrocyklooktylopirazolokannabinoidowe
|
US8378096B2
(en)
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
WO2007038610A2
(en)
|
2005-09-26 |
2007-04-05 |
President & Fellows Of Harvard College |
Use of natural products for treatment of neurological disorders
|
CA2521272A1
(en)
|
2005-10-04 |
2007-04-04 |
Bernard Charles Sherman |
Capsules comprising topiramate
|
WO2007047351A2
(en)
|
2005-10-13 |
2007-04-26 |
Orexigen Therapeutics, Inc. |
Methods for treating hypertension in overweight and obese individuals
|
US7378434B2
(en)
|
2005-10-14 |
2008-05-27 |
Mutual Pharmaceutical Company, Inc. |
Metaxalone products, method of manufacture, and method of use
|
DE202005016250U1
(de)
|
2005-10-17 |
2006-01-26 |
Helm Ag |
Topiramat und pharmazeutische Formulierungen davon
|
JP2009512715A
(ja)
|
2005-10-21 |
2009-03-26 |
ノバルティス アクチエンゲゼルシャフト |
レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
EP1951692B1
(en)
|
2005-11-07 |
2010-08-18 |
Irm Llc |
Oxazole and thiazole ppar modulator
|
JP2009514974A
(ja)
|
2005-11-07 |
2009-04-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Pparモジュレーターとしての化合物および組成物
|
BRPI0618335A2
(pt)
|
2005-11-07 |
2011-08-23 |
Irm Llc |
compostos e composições como moduladores de ppar
|
CN101370488B
(zh)
|
2005-11-22 |
2012-07-18 |
奥雷西根治疗公司 |
增加胰岛素敏感性的组合物
|
WO2007089318A2
(en)
|
2005-11-23 |
2007-08-09 |
Orexigen Therapeutics, Inc. |
Compositions and methods for reducing food cravings
|
EP1959947A2
(en)
|
2005-12-15 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
AR058558A1
(es)
|
2005-12-21 |
2008-02-13 |
Schering Corp |
Derivados de anilina sustituida utiles como antagonistas de la histamina h3
|
BRPI0620386A2
(pt)
|
2005-12-21 |
2011-12-20 |
Schering Corp |
composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
AU2006331882A1
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
|
WO2007084290A2
(en)
|
2006-01-12 |
2007-07-26 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
|
US7824694B2
(en)
|
2006-01-12 |
2010-11-02 |
Allergan, Inc. |
Methods for enhancing therapeutic effects of a neurotoxin
|
JP2009525961A
(ja)
|
2006-01-20 |
2009-07-16 |
シェーリング コーポレイション |
異常脂質血症の処置のためのニコチン酸受容体アゴニストとしての複素環
|
WO2007119178A2
(en)
|
2006-01-23 |
2007-10-25 |
Neuren Pharmaceuticals Limited |
Infusion pump
|
CA2627692A1
(en)
|
2006-01-30 |
2007-08-02 |
Irm Llc |
Spiro imidazole derivatives as ppar modulators
|
WO2007089557A2
(en)
|
2006-01-30 |
2007-08-09 |
Irm Llc |
Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
|
KR20080086529A
(ko)
|
2006-01-30 |
2008-09-25 |
아이알엠 엘엘씨 |
Ppar 조절제로서의 화합물 및 조성물
|
US20070191371A1
(en)
|
2006-02-14 |
2007-08-16 |
Kalypsys, Inc. |
Heterocyclic modulators of ppar
|
LT1988910T
(lt)
|
2006-02-28 |
2018-01-10 |
Kodiak Sciences Inc. |
Akriloiloksietilfosforilcholiną turintys polimero konjugatai ir jų gavimo būdas
|
WO2007099388A1
(en)
|
2006-03-01 |
2007-09-07 |
Glade Organics Private Limited |
An improved process for the manufacture of topiramate
|
WO2007106862A2
(en)
|
2006-03-14 |
2007-09-20 |
Kinemed, Inc. |
The use of statins to stimulate neurogenesis
|
WO2007108009A1
(en)
|
2006-03-17 |
2007-09-27 |
Alembic Limited |
A process for purification of topiramate
|
US20110263693A1
(en)
|
2006-03-31 |
2011-10-27 |
Dana-Farber Cancer Institute, Inc. |
Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
|
US20070232648A1
(en)
|
2006-03-31 |
2007-10-04 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US9561188B2
(en)
*
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
DE102006015734A1
(de)
|
2006-04-04 |
2007-10-11 |
Hermann, Holger Lars, Dr. |
Kombinationspräparate aus Modafinil, Ritalin und Topiramat und deren Derivaten zur Behandlung von Kokainabhängigkeit und/oder Impulskontrollstörung
|
CN101420958A
(zh)
|
2006-04-06 |
2009-04-29 |
挪瓦卡尔迪阿公司 |
共投与腺苷a1受体拮抗剂和抗惊厥药
|
US7659281B2
(en)
|
2006-04-25 |
2010-02-09 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors
|
US8945623B2
(en)
|
2006-05-03 |
2015-02-03 |
Warsaw Orthopedic, Inc. |
Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
|
US8840933B2
(en)
|
2006-05-03 |
2014-09-23 |
Warsaw Orthopedic, Inc. |
Method of treating neuronal injury by administering magnesium chloride and PEG
|
US8377994B2
(en)
|
2006-05-10 |
2013-02-19 |
Evonik Degussa GmeH |
Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
|
EP2026790A2
(en)
|
2006-05-19 |
2009-02-25 |
Janssen Pharmaceutica, N.V. |
Co-therapy for the treatment of epilepsy and related disorders
|
WO2007137164A2
(en)
|
2006-05-19 |
2007-11-29 |
Janssen Pharmaceutica N.V. |
Co-therapy for the treatment of epilepsy and related disorders
|
JP5230613B2
(ja)
|
2006-05-23 |
2013-07-10 |
テラコス・インコーポレイテッド |
グルコース輸送体阻害剤およびその使用方法
|
WO2008010231A2
(en)
|
2006-05-26 |
2008-01-24 |
Alembic Limited |
A process for the purification of topiramate
|
AU2007256931B2
(en)
|
2006-05-30 |
2013-01-24 |
Janssen Pharmaceutica N.V. |
Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
|
CN101511807A
(zh)
|
2006-06-29 |
2009-08-19 |
詹森药业有限公司 |
组胺h3受体的取代的苯甲酰胺调节剂
|
CA2656075A1
(en)
|
2006-06-29 |
2008-01-03 |
Janssen Pharmaceutica N.V. |
Butyl and butynyl benzyl amine compounds
|
WO2008002818A1
(en)
|
2006-06-29 |
2008-01-03 |
Janssen Pharmaceutica N.V. |
Substituted aminomethyl benzamide compounds
|
AU2007265242A1
(en)
|
2006-06-29 |
2008-01-03 |
Janssen Pharmaceutica N.V. |
Substituted benzyl amine compounds
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
US20080009534A1
(en)
|
2006-07-07 |
2008-01-10 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
US20080014252A1
(en)
|
2006-07-14 |
2008-01-17 |
Delprete Keith |
Topical compositions with long lasting effect
|
US9744137B2
(en)
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20080078382A1
(en)
|
2006-09-20 |
2008-04-03 |
Lemahieu Edward |
Methods and Systems of Delivering Medication Via Inhalation
|
JP2010508997A
(ja)
|
2006-11-09 |
2010-03-25 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
減量薬を投与するための方法
|
EP1973528B1
(en)
|
2006-11-17 |
2012-11-07 |
Supernus Pharmaceuticals, Inc. |
Sustained-release formulations of topiramate
|
WO2008070670A2
(en)
|
2006-12-04 |
2008-06-12 |
Supernus Pharmaceuticals, Inc. |
Enhanced immediate release formulations of topiramate
|
US20080153874A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Allergan Inc. |
Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
|
EP2150248A4
(en)
|
2007-01-16 |
2011-06-29 |
Univ Johns Hopkins |
GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE
|
US20100197610A1
(en)
|
2007-01-23 |
2010-08-05 |
Baylor College Of Medicine |
Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
|
WO2008089521A1
(en)
|
2007-01-25 |
2008-07-31 |
Verva Pharmaceuticals Ltd |
Insulin sensitisers and methods of treatment
|
US20100119512A1
(en)
|
2007-01-25 |
2010-05-13 |
Joslin Diabetes Center |
Methods of diagnosing, treating, and preventing increased vascular permeability
|
CA2677205A1
(en)
|
2007-01-31 |
2008-08-07 |
University Of Virginia Patent Foundation |
Topiramate plus naltrexone for the treatment of addictive disorders
|
AU2007346591A1
(en)
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of ADHD
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
WO2008098195A2
(en)
|
2007-02-09 |
2008-08-14 |
Todd Maibach |
Film comprising nitroglycerin
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
WO2008106659A2
(en)
|
2007-03-01 |
2008-09-04 |
Memory Pharmaceuticals Corporation |
Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith
|
WO2008109343A1
(en)
|
2007-03-01 |
2008-09-12 |
Memory Pharmaceuticals Corporation |
Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
|
WO2008115797A1
(en)
|
2007-03-16 |
2008-09-25 |
Pavo, Inc. |
Therapeutic compositions and methods
|
WO2008121882A1
(en)
|
2007-03-29 |
2008-10-09 |
Novacardia, Inc. |
Improved methods of administration of adenosine a1 receptor antagonists
|
RU2492175C2
(ru)
|
2007-04-02 |
2013-09-10 |
Теракос, Инк. |
Бензиловые производные гликозидов и способы их применения
|
ES2438768T3
(es)
|
2007-04-11 |
2014-01-20 |
Omeros Corporation |
Composiciones y métodos para la profilaxis y el tratamiento de adicciones
|
US8198305B2
(en)
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
WO2008148064A1
(en)
|
2007-05-23 |
2008-12-04 |
Sunesis Pharmaceuticals, Inc. |
Weight loss treatment
|
WO2008148023A2
(en)
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating neurological disorders
|
US8071557B2
(en)
|
2007-06-13 |
2011-12-06 |
Vivus, Inc. |
Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
|
US20090004254A1
(en)
|
2007-06-19 |
2009-01-01 |
Todd Maibach |
Film comprising active drugs
|
US20120238554A1
(en)
*
|
2007-07-02 |
2012-09-20 |
Cowen Neil M |
Salts of potassium atp channel openers and uses thereof
|
AU2008279169A1
(en)
|
2007-07-23 |
2009-01-29 |
Biotie Therapies, Inc |
4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
|
US20090030403A1
(en)
|
2007-07-27 |
2009-01-29 |
Leyde Kent W |
Methods and Systems for Attenuating the Tolerance Response to a Drug
|
US20090082400A1
(en)
|
2007-07-31 |
2009-03-26 |
Ving Lee |
Soluble pyrone analogs methods and compositions
|
KR20100051829A
(ko)
|
2007-07-31 |
2010-05-18 |
리머릭 바이오파르마 인코오포레이티드 |
인산화된 피론 유사체 및 방법
|
EP2185535A1
(en)
|
2007-08-08 |
2010-05-19 |
Janssen Pharmaceutica N.V. |
Sulfamide derivative useful for the treatment of epilepsy
|
US7943653B2
(en)
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
BRPI0815708B8
(pt)
|
2007-08-23 |
2021-05-25 |
Theracos Sub Llc |
composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
|
CA2697990A1
(en)
|
2007-08-27 |
2009-03-05 |
University Of Virginia Patent Foundation |
Medication combinations for the treatment of alcoholism and drug addiction
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
HUE043897T2
(hu)
|
2007-09-25 |
2019-09-30 |
Solubest Ltd |
Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
|
US20090087483A1
(en)
|
2007-09-27 |
2009-04-02 |
Sison Raymundo A |
Oral dosage combination pharmaceutical packaging
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
US9145453B2
(en)
|
2007-09-28 |
2015-09-29 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
US20120082659A1
(en)
|
2007-10-02 |
2012-04-05 |
Hartmut Land |
Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
|
US20120114670A1
(en)
|
2007-10-02 |
2012-05-10 |
University Of Rochester |
Methods and compositions related to synergistic responses to oncogenic mutations
|
WO2009045443A2
(en)
|
2007-10-02 |
2009-04-09 |
The University Of Rochester |
Methods and compositions related to synergistic responses to oncogenic mutations
|
WO2009054544A1
(en)
|
2007-10-26 |
2009-04-30 |
Eisai R & D Management Co., Ltd. |
Ampa receptor antagonists for parkinson's disease and movement disorders
|
JP2011506318A
(ja)
*
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
経口医薬製剤
|
EP2227085A4
(en)
|
2007-12-06 |
2013-10-09 |
Berg Pharma Llc |
INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
|
WO2009079521A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100317572A1
(en)
|
2007-12-20 |
2010-12-16 |
Neurosearch A/S |
Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
|
CN102015769B
(zh)
|
2008-01-17 |
2014-12-10 |
Irm责任有限公司 |
改进的抗-trkb抗体
|
KR20100127799A
(ko)
|
2008-02-28 |
2010-12-06 |
유니버시티 오브 버지니아 페이턴트 파운데이션 |
세로토닌 운반체 유전자 및 알콜중독의 치료
|
US8138169B2
(en)
|
2008-04-11 |
2012-03-20 |
Comgenrx, Inc. |
Combination therapy for bipolar disorder
|
WO2009131692A1
(en)
|
2008-04-23 |
2009-10-29 |
The Board Of Trustees Of The University Of Alabama |
Substrates for delivery of physiologically active agents
|
US20090270469A1
(en)
|
2008-04-25 |
2009-10-29 |
Auspex Pharmaceuticals, Inc. |
Substituted oxazolidinones
|
AU2009242127B2
(en)
|
2008-04-29 |
2014-03-27 |
Pharnext |
New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response
|
PT2282778T
(pt)
|
2008-04-29 |
2017-04-27 |
Pharnext |
Novas abordagens terapêuticas no tratamento da doença de alzheimer e doenças relacionadas através de uma modulação da angiogénese
|
EA024147B1
(ru)
|
2008-04-29 |
2016-08-31 |
Фарнекст |
Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
|
US20090304789A1
(en)
|
2008-06-09 |
2009-12-10 |
Thomas Najarian |
Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
|
US8580298B2
(en)
|
2008-06-09 |
2013-11-12 |
Vivus, Inc. |
Low dose topiramate/phentermine composition and methods of use thereof
|
US8592424B2
(en)
|
2008-06-30 |
2013-11-26 |
Afgin Pharma Llc |
Topical regional neuro-affective therapy
|
US20110212944A1
(en)
|
2008-07-01 |
2011-09-01 |
Julie Liu |
2-oxo-1-pyrrolidine derivatives
|
AU2009270849B2
(en)
|
2008-07-17 |
2013-11-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US9623000B2
(en)
|
2008-07-31 |
2017-04-18 |
Dekel Pharmaceuticals Ltd |
Compositions and methods for treating inflammatory disorders
|
US20110207718A1
(en)
|
2008-08-06 |
2011-08-25 |
Gosforth Centre (Holdings) Pty Ltd. |
Compositions and methods for treating psychiatric disorders
|
US20100074973A1
(en)
|
2008-08-27 |
2010-03-25 |
Auspex Pharmaceuticals, Inc. |
Thioxanthene modulators of dopamine d2 receptors
|
US20100056546A1
(en)
|
2008-09-04 |
2010-03-04 |
Auspex Pharmaceuticals, Inc. |
Sulfonylurea inhibitors of atp-sensitive potassium channels
|
US20100190752A1
(en)
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
MX2011002339A
(es)
|
2008-09-05 |
2011-04-04 |
Gruenenthal Gmbh |
Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propi l)-fenol y un antiepileptico.
|
US20100105755A1
(en)
|
2008-09-12 |
2010-04-29 |
Auspex Pharmaceuticals, Inc. |
Substituted benzamide modulators of dopamine receptor
|
US20100119622A1
(en)
|
2008-09-15 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
|
US8436015B2
(en)
|
2008-09-15 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US20100119624A1
(en)
|
2008-09-17 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
Benzisoxazole modulators of d2 receptor and/or 5-ht2a receptor
|
US20110244057A1
(en)
|
2008-09-25 |
2011-10-06 |
Ehrenberg Bruce L |
Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
|
US20100159033A1
(en)
|
2008-09-29 |
2010-06-24 |
Auspex Pharmaceuticals, Inc. |
Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
|
US20100266711A1
(en)
|
2008-09-29 |
2010-10-21 |
Auspex Pharmaceuticals, Inc. |
Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor
|
CN102186461A
(zh)
|
2008-10-14 |
2011-09-14 |
麦克内尔股份公司 |
多部分口腔内剂型及其用途
|
WO2010045416A2
(en)
|
2008-10-16 |
2010-04-22 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
US20100167988A1
(en)
|
2008-10-22 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Ethoxyphenylmethyl inhibitors of sglt2
|
US20100166887A1
(en)
|
2008-10-22 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
DIBENZO[b,e][1,4]DIAZEPINE MODULATORS OF DOPAMINE RECEPTORS, SEROTONIN RECEPTORS, ADRENERGIC RECEPTORS, ACETYLCHOLINE RECEPTORS, AND/OR HISTAMINE RECEPTORS
|
US20100167989A1
(en)
|
2008-10-23 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Isopropoxyphenylmethyl inhibitors of sglt2
|
US20100113432A1
(en)
|
2008-11-05 |
2010-05-06 |
Auspex Pharmaceuticals, Inc. |
Phenothiazine modulators of d2 receptors and 5-ht2 receptors
|
US20100120861A1
(en)
|
2008-11-13 |
2010-05-13 |
Auspex Pharmaceuticals, Inc. |
Benzoic acid inhibitors of atp-sensitive potassium channels
|
US20100125085A1
(en)
|
2008-11-17 |
2010-05-20 |
Auspex Pharmaceuticals, Inc. |
Pyridoindole modulators of nmda receptor and acetylcholinesterase
|
US20100124541A1
(en)
|
2008-11-19 |
2010-05-20 |
Auspex Pharmaceuticals, Inc. |
Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
|
US20100130615A1
(en)
|
2008-11-21 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Sulfonylurea inhibitors of atp-sensitive potassium channels
|
US20100129311A1
(en)
|
2008-11-21 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Phenylalanine amide inhibitors of atp-sensitive potassium channels
|
US20100130528A1
(en)
|
2008-11-21 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Adamantane modulators of nmda receptor and/or 5ht3 receptor
|
US20100130582A1
(en)
|
2008-11-24 |
2010-05-27 |
Auspex Pharmaceuticals, Inc. |
Indolinone modulators of dopamine receptor
|
US20100143507A1
(en)
|
2008-12-09 |
2010-06-10 |
Auspex Pharmaceuticals, Inc. |
Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
|
WO2010075086A2
(en)
|
2008-12-15 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Pyrrolidinone inhibitors of pde-4
|
WO2010071750A1
(en)
|
2008-12-19 |
2010-06-24 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
US20110281795A1
(en)
|
2009-01-28 |
2011-11-17 |
Songnian Lin |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US8324384B2
(en)
|
2009-02-12 |
2012-12-04 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
WO2010098948A1
(en)
|
2009-02-13 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
|
WO2010098994A1
(en)
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
WO2010098888A1
(en)
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
|
US20100286762A1
(en)
|
2009-03-18 |
2010-11-11 |
Musc Foundation For Research Development |
Compositions and Methods for Ameliorating Clinical Electrical Disturbances
|
EP2414542B1
(en)
|
2009-03-30 |
2017-08-30 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Methods of predicting clinical course and treating multiple sclerosis
|
US8778998B2
(en)
|
2009-04-10 |
2014-07-15 |
Auspex Pharmaceuticals, Inc. |
Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
|
MX2011012140A
(es)
|
2009-05-14 |
2012-02-28 |
Gilead Sciences Inc |
Ranolazina para el tratamiento de problemas del snc.
|
US20100317730A1
(en)
|
2009-06-12 |
2010-12-16 |
Shaya Elias K |
Treatment for menopausal and perimenopausal vasomotor symptons
|
WO2010147830A2
(en)
|
2009-06-15 |
2010-12-23 |
Auspex Pharmaceuticals, Inc. |
Aminothiazole modulators of beta-3-adrenoreceptor
|
WO2011008298A2
(en)
|
2009-07-16 |
2011-01-20 |
Nectid, Inc. |
Novel axomadol dosage forms
|
US20110014296A1
(en)
|
2009-07-17 |
2011-01-20 |
National Chiao Tung University |
Drug Delivery Nanodevice, its Preparation Method and Uses Thereof
|
US20110015663A1
(en)
|
2009-07-17 |
2011-01-20 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
US20110257260A1
(en)
|
2009-07-21 |
2011-10-20 |
Auspex Pharmaceuticals, Inc. |
3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
|
WO2011023392A1
(en)
|
2009-08-28 |
2011-03-03 |
Grünenthal GmbH |
Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic
|
EP2477610A1
(en)
*
|
2009-09-17 |
2012-07-25 |
Upsher-Smith Laboratories, Inc. |
A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
|
NO2480669T3
(pt)
|
2009-09-25 |
2018-04-07 |
|
|
US20110082407A1
(en)
|
2009-10-01 |
2011-04-07 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
ES2895226T3
(es)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
|
WO2011050008A2
(en)
|
2009-10-19 |
2011-04-28 |
Amylin Pharmaceuticals, Inc. |
Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
|
EP2322163A1
(en)
|
2009-11-03 |
2011-05-18 |
Pharnext |
New therapeutics approaches for treating alzheimer disease
|
WO2011060363A2
(en)
|
2009-11-16 |
2011-05-19 |
Auspex Pharmaceuticals, Inc. |
Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
|
US20130109674A1
(en)
|
2009-12-18 |
2013-05-02 |
Achelios Therapeutics Llc |
Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
|
US20110206780A1
(en)
|
2010-01-06 |
2011-08-25 |
Auspex Pharmaceuticals, Inc. |
Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors
|
BR112012016799A2
(pt)
|
2010-01-07 |
2019-10-08 |
Vivus Inc |
tratamento da síndrome de apneia obstrutiva do sono com uma combinação de um inibidor da anidrase carbônica e um agente ativo adicional
|
WO2011085181A1
(en)
|
2010-01-08 |
2011-07-14 |
Eurand, Inc. |
Taste masked topiramate composition and an orally disintegrating tablet comprising the same
|
US8461171B2
(en)
|
2010-02-09 |
2013-06-11 |
QRxPharma Ltd. |
Hybrid opioid compounds and compositions
|
US20110200671A1
(en)
*
|
2010-02-17 |
2011-08-18 |
Sun Pharma Advanced Research Company Ltd. |
Method of treating a disease condition susceptible to baclofen therapy
|
US20110206782A1
(en)
|
2010-02-24 |
2011-08-25 |
Auspex Pharmaceuticals, Inc. |
Piperidine modulators of dopamine receptor
|
WO2011107855A2
(en)
|
2010-03-04 |
2011-09-09 |
Torrent Pharmaceuticals Limited |
Sustained release oral liquid suspension dosage form
|
GB201003734D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Delayed prolonged drug delivery
|
GB201003731D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Immediate/delayed drug delivery
|
GB201003766D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Pulsatile drug release
|
DK2547679T3
(en)
|
2010-03-19 |
2016-01-11 |
Pfizer |
2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor
|
WO2011120044A1
(en)
|
2010-03-26 |
2011-09-29 |
Duke University |
Conjugated neuroactive steroid compositions and methods of use
|
WO2011126910A2
(en)
|
2010-03-30 |
2011-10-13 |
Algynomics Inc. |
Compositions and methods for the treatment of somatosensory disorders
|
US9695264B2
(en)
|
2010-04-01 |
2017-07-04 |
Ppg Industries Ohio, Inc. |
High functionality polyesters and coatings comprising the same
|
KR101927068B1
(ko)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
WO2011143721A1
(en)
|
2010-05-21 |
2011-11-24 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating neurodegenerative disorders
|
CN103096895B
(zh)
|
2010-06-24 |
2016-06-01 |
塔夫茨大学信托人 |
烟酸模拟物及其使用的方法
|
JP5925770B2
(ja)
|
2010-06-24 |
2016-05-25 |
トラスティーズ オブ タフツ カレッジ |
ナイアシン模倣体、およびその使用方法
|
US20120003312A1
(en)
|
2010-06-30 |
2012-01-05 |
Aptapharma, Inc. |
Multilayer Minitablets with Different Release Rates
|
EP2422787A1
(en)
|
2010-08-17 |
2012-02-29 |
Neurotec Pharma, S.L. |
Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2012033874A1
(en)
|
2010-09-10 |
2012-03-15 |
Chipkin Richard E |
Method of treating compulsive self-injurious behaviors
|
WO2012056372A1
(en)
|
2010-10-29 |
2012-05-03 |
Pfizer Inc. |
N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
|
EP2640395A4
(en)
|
2010-11-08 |
2014-01-22 |
Omeros Corp |
TREATMENT OF DISEASES ASSOCIATED WITH SEARCH AND PULSE CONTROL BY PDE7 INHIBITORS
|
WO2012074561A2
(en)
|
2010-11-30 |
2012-06-07 |
Columbia Northwest Pharmaceuticals Llc |
Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
|
EP2479691A1
(en)
|
2011-01-21 |
2012-07-25 |
Johan Cederlund |
Pharmaceutical product and communication tool
|
EP2667875A4
(en)
|
2011-01-24 |
2014-07-30 |
Inceptum Res & Therapeutics Inc |
COMPOSITIONS COMPRISING PROSTAGLANDIN FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
|
US20140050728A1
(en)
|
2011-01-28 |
2014-02-20 |
Board Of Regents Of The University Of Nebraska |
Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
|
US20120128683A1
(en)
|
2011-11-22 |
2012-05-24 |
Shantha Totada R |
Autism treatment
|
US8652527B1
(en)
*
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9101545B2
(en)
*
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|